BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28233747)

  • 1. Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil.
    Almeida-Carvalho SR; Gomes-Ferraz ML; Loureiro-Matos CA; Benedito-Silva AT; Carvalho-Filho RJ; Renato-Perez R; Miziara-Gonzalez A; Salzedas-Netto AA; Szejnfeld D; D'Ippolito G; Pereira-Lanzoni V; Souza-Silva I
    Ann Hepatol; 2017; 16(2):255-262. PubMed ID: 28233747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
    Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
    World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
    Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Sarpel U; Spivack JH; Berger Y; Heskel M; Aycart SN; Sweeney R; Edwards MP; Labow DM; Kim E
    HPB (Oxford); 2016 May; 18(5):411-8. PubMed ID: 27154804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
    Ramanathan R; Sharma A; Lee DD; Behnke M; Bornstein K; Stravitz RT; Sydnor M; Fulcher A; Cotterell A; Posner MP; Fisher RA
    Transplantation; 2014 Jul; 98(1):100-6. PubMed ID: 24503764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
    Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
    BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
    Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
    Kikuchi L; Oliveira CP; Alvares-da-Silva MR; Tani CM; Diniz MA; Stefano JT; Chagas AL; Alencar RS; Vezozzo DC; Santos GR; Campos PB; Alves VA; Ratziu V; Carrilho FJ
    Am J Clin Oncol; 2016 Oct; 39(5):428-32. PubMed ID: 25268068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
    de'Angelis N; Landi F; Carra MC; Azoulay D
    World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
    Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
    Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.